



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2019-20

July 29, 2019

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
BSE ID: AARTIDRUGS  
**BSE CODE – 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India  
Limited,**  
“Exchange Plaza”, Bandra - Kurla  
Complex, Bandra (E), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Sub: Press Release**

Please find enclosed herewith copy of the press release issued by the Company on July 29, 2019.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

  
RUSHIKESH DEOLE

**COMPANY SECRETARY**

ICSI M.No.: A54527





# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

## Press release for June'19

In June quarter, company recorded the consolidated quarterly revenue of Rs.405.43 Crores with year-on-year growth of 8.32%. Domestic sales of the API segment grew by approximately 10%. Around 89% of the overall API segment growth was driven by volume increase and rest due to rate variance. Formulation segment revenues grew by approximately 25% on year-on-year basis.

Consolidated EBITDA for the quarter ended June'19 is Rs. 54.77 Crores, up by 2.33% and consolidated profit after tax for the quarter ended June'19 is Rs.22.45 Crores, down by 3.95% due to higher effective tax rate as compared to Jun'18 quarter. Company was able to improve its gross margins as compared to previous quarter due to better operational efficiency and expects to improve further. API segment EBITDA margin improved by approximately 1.73% as compared to previous Mar'19 quarter and company expects it to improve further. Due to improved working capital management, Company was able to further reduce its Debt/Equity ratio to 0.90 as of Jun'19 on consolidated basis.

Recently expanded Anti-Diabetic facility should drive topline growth in second half of financial year 2019-20. Further CAPEX is in progress to expand few capacities in anti-inflammatory therapeutic category. Also, Company expects more export markets to open up for formulation division leading to better margins in that segment.

**FOR AARTI DRUGS LIMITED**

ADHISH P. PATIL  
CHIEF FINANCIAL OFFICER